Mapping CSF biomarker profiles onto NIA–AA guidelines for Alzheimer’s disease-Reference-Cited by-同舟云学术

Mapping CSF biomarker profiles onto NIA–AA guidelines for Alzheimer’s disease

Published:2015-08-08 Issue:7 Volume:266 Page:587-597
ISSN:0940-1334
Container-title:European Archives of Psychiatry and Clinical Neuroscience
language:en
Short-container-title:Eur Arch Psychiatry Clin Neurosci

Author:

Alexopoulos Panagiotis,Roesler Jennifer,Thierjung Nathalie,Werle Lukas,Buck Dorothea,Yakushev Igor,Gleixner Lena,Kagerbauer Simone,Ortner Marion,Grimmer Timo,Kübler Hubert,Martin Jan,Laskaris Nikolaos,Kurz Alexander,Perneczky Robert

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00406-015-0628-7.pdf

Reference38 articles.

1. McKhann GM (2011) Changing concepts of Alzheimer disease. JAMA 305(23):2458–2459. doi: 10.1001/jama.2011.810

2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269. doi: 10.1016/j.jalz.2011.03.005

3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):280–292. doi: 10.1016/j.jalz.2011.03.003

4. Martins-de-Souza D (2010) Is the word ‘biomarker’ being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260(7):561–562. doi: 10.1007/s00406-010-0105-2

5. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389. doi: 10.1001/archneurol.2008.596

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study;European Archives of Psychiatry and Clinical Neuroscience;2023-10-28

2. Clinical characteristics of patients with suspected Alzheimer’s disease within a CSF Aß-ratio grey zone;Neurological Research and Practice;2023-08-03

3. Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease;European Journal of Nuclear Medicine and Molecular Imaging;2023-06-05

4. Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration;Neurology;2021-01-06

5. Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease;Clinics in Laboratory Medicine;2020-09